产品
编 号：F424444
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 679809-58-6
产品详情
生物活性：
Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19.
体内研究：
Enoxaparin (1 mg/kg; SC; once every 6 h for 8 times) reduces oxidative damage, inflammation and astrocytosis following TBI (traumatic brain injury) in the rat.Animal Model:Adult male Wistar rats (350-450 g, TBI-treated)
Dosage:0 mg/kg, 1 mg/kg
Administration:SC, once every 6 h, starting at 1 h, and finishing at 43 h after the TBI induction.
Result:Significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1β and active caspase-3 overexpressions as well as neurodegeneration following TBI. Reduce oxidative damage, inflammation and astrocytosis following TBI in the rat.
体外研究：
Enoxaparin (0-70 μg/mL, 90 min) enhances AAT (alpha-1-antitrypsin) inhibition of both TMPRSS2 (Transmembrane Protease 2) activity and infection of hAEc (human airway epithelial cells) with HCoV-229E.
Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19.
体内研究：
Enoxaparin (1 mg/kg; SC; once every 6 h for 8 times) reduces oxidative damage, inflammation and astrocytosis following TBI (traumatic brain injury) in the rat.Animal Model:Adult male Wistar rats (350-450 g, TBI-treated)
Dosage:0 mg/kg, 1 mg/kg
Administration:SC, once every 6 h, starting at 1 h, and finishing at 43 h after the TBI induction.
Result:Significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1β and active caspase-3 overexpressions as well as neurodegeneration following TBI. Reduce oxidative damage, inflammation and astrocytosis following TBI in the rat.
体外研究：
Enoxaparin (0-70 μg/mL, 90 min) enhances AAT (alpha-1-antitrypsin) inhibition of both TMPRSS2 (Transmembrane Protease 2) activity and infection of hAEc (human airway epithelial cells) with HCoV-229E.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备